Loading news...
Eli Lilly has strong momentum thanks to its leadership in the weight loss market. Vertex Pharmaceuticals' core franchise and newer approvals could drive top-line growth for a long time.
Bamco Inc. NY acquired a new stake in shares of Vertex, Inc. (NASDAQ: VERX) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm acquired 248,042 shares of the company's stock, valued at approximately $6,149,000. Bamco Inc. NY owned 0.16% of Vertex at the end of the
The biotech company is the leader in the cystic fibrosis market and is quickly expanding into other treatment areas. Vertex forecasts its newer medicines may add $500 million to revenue this year.
Roofing Innovator Propels to Over $600M in Revenue with 30 Acquisitions in Three Years, Leveraging ServiceTitan's Enterprise-Grade Platform Roofing Innovator Propels to Over $600M in Revenue with 30 Acquisitions in Three Years, Leveraging ServiceTitan's Enterprise-Grade Platform
Vertex, Inc. (NASDAQ: VERX - Get Free Report) has received an average rating of "Hold" from the fifteen analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average
Reduced holding by 384,415 shares; estimated transaction value of $8.32 million based on quarterly average price Quarter-end position value decreased by $26.01 million, reflecting both share sales and price changes Represents a 1.08% shift in 13F reportable assets under management (AUM) Post-trade, the fund owns 3,419,994 shares, valued at $68.30 million The position now accounts for 8.85% of AUM, which places it outside the fund's top five holdings
Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease.
Vertex stock popped late Monday on promising test results for a drug that could treat a chronic autoimmune disease that destroys the kidneys.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). The trial met its primary objective. In the interim analysis population, patients treated with povetacicept ach.
Vertex (NASDAQ: VERX - Get Free Report) and i3 Verticals (NASDAQ: IIIV - Get Free Report) are both computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings. Institutional and Insider Ownership 70.3% of Vertex
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026, at 10:00 a.m. ET. Susie Lisa, Senior Vice President, Investor Relations, and Miroslava Minkova, Executive Director, Investor Relation.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatmen.
Vertex, Inc. (VERX) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Banco Santander S.A. lessened its holdings in shares of Vertex, Inc. (NASDAQ: VERX) by 47.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 177,826 shares of the company's stock after selling 160,174 shares during the quarter. Banco Santander S.A.
KING OF PRUSSIA, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX), a global provider of tax technology solutions, today announced that Chris Young, President and Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at two upcoming conferences.
Vertex, Inc. (NASDAQ: VERX - Get Free Report) Director Eric Andersen bought 40,000 shares of the business's stock in a transaction dated Friday, February 20th. The stock was acquired at an average price of $12.91 per share, for a total transaction of $516,400.00. Following the purchase, the director directly owned 150,341 shares in the company, valued
Vertex, Inc. (NASDAQ: VERX - Get Free Report)'s stock price gapped up prior to trading on Thursday after an insider bought additional shares in the company. The stock had previously closed at $12.09, but opened at $12.93. Vertex shares last traded at $13.0590, with a volume of 626,927 shares trading hands. Specifically, insider Jeffrey Westphal acquired
It was the subject of a bullish analyst update. In that note, pundit Adam Hotchkiss reiterated his buy recommendation and lofty price target.
I believe Vertex Pharmaceuticals Incorporated's bull run has come to an end. There's a divergence between its stock price growth over the past 5 months and the performance of Journavx and the cystic fibrosis franchise. So, in Q4, Trikafta+Kaftrio sales declined 3.1% quarter-on-quarter to about $2.57 billion, missing my "base case" scenario by $45 million.
Vertex Pharmaceuticals is the leader in cystic fibrosis treatment. The company has also expanded into other areas in recent years, winning approval for two new drugs.